Intervention

IBI308

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting1

Common conditions3

Lead sponsors shown3

Clinical trials

3 shown

Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLCNCT03872661 · 2019-03-01

RECRUITING

Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide ChemotherapyNCT04056949 · 2019-08-05

UNKNOWN

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLCNCT03150875 · 2017-09-01

COMPLETED

Common conditions

Extensive-Stage Small Cell Lung Cancer1 Lung Cancer Stage III1 Non-small Cell Lung Cancer1

Leading sponsors

Innovent Biologics (Suzhou) Co. Ltd. 1 Junling Li 1 Sun Yat-sen University 1

Trial status mix

COMPLETED1

RECRUITING1

UNKNOWN1

Phase mix

PHASE22

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.